Simplified Comorbidity Score and Eastern Cooperative Oncology Group Performance Score Predicts Survival in Patients Receiving Organ-preserving Treatment for Bladder Cancer

Background/Aim: This study investigated three comorbidity scales and the Eastern Cooperative Oncology Group performance score (ECOG-PS) for survival in patients receiving local irradiation for bladder cancer. Patients and Methods: Sixty-four patients receiving organ-preserving radio-chemotherapy or radiotherapy for urinary bladder cancer were retrospectively evaluated. Charlson Comorbidity Index (CCI), Simplified Comorbidity Score (SCS), Age-Adjusted Charlson Comorbidity Index (AAC) and ECOG-PS were analyzed for associations with survival. Results: Patients with a SCS of 0-7 points had a significantly better survival than those with 8-18 points (p=0.018). Five-year survival rates were 64% and 32%, respectively. Patients with ECOG-PS of 0-1 had a significantly better 5-year survival than patients with ECOG-PS of 2-3 (64% vs. 0%, p<0.001). For CCI (p=0.16) and AAC (p=0.49), a significant association with survival was not observed. Conclusion: SCS and ECOG-PS were significantly associated with survival in patients irradiated for bladder cancer and can help estimate the prognoses of these patients.